Company Description
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases.
The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure.
It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking.
The company incorporates Prolaio’s cardiovascular data collection and analytics platform, which includes FDA-cleared algorithms and high-density patient data, to support drug development and clinical intelligence.
The company engages in strategic in-licensing and acquisitions to expand its pipeline of targeted treatments.
Kardigan serves biopharmaceutical companies, cardiovascular researchers, and healthcare providers in the cardiology sector.
The company was formerly known as EnCarda, Inc. and changed its name to Kardigan, Inc. in December 2024.
The company was founded in 2023 and is based in Princeton, New Jersey.
| Country | United States |
| Founded | 2023 |
| IPO Date | Jun 18, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 241 |
| CEO | Tassos Anastasios Gianakakos |
Contact Details
Address: 506 Carnegie Center Drive, Suite 201 Princeton, New Jersey 08540 United States | |
| Phone | (415) 573-3220 |
| Website | kardigan.bio |
Stock Details
| Ticker Symbol | KARD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 2123613 |
| CUSIP Number | 485925101 |
| ISIN Number | US4859251013 |
| Employer ID | 93-2994203 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Tassos Gianakakos | Chief Executive Officer, Director, and Chair |
| Brianne Puglisi | Chief Financial Officer |
| Jay Edelberg | Chief Medical Officer |
| Andy Pasternak | Chief Strategy Officer |
| John B. Moriarty, Jr. | Chief Legal Officer and Corporate Secretary |
| Paul Berns | Director |
| Douglas Giordano | Director |
| David Meeker, M.D. | Director |
| Kim Popovits | Director |
| Tim Walbert | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 29, 2026 | SCHEDULE 13G | Filing |
| Jun 29, 2026 | SCHEDULE 13D | Filing |
| Jun 25, 2026 | SCHEDULE 13D | Filing |
| Jun 23, 2026 | 8-K | Current Report |
| Jun 18, 2026 | 424B4 | Prospectus |
| Jun 17, 2026 | EFFECT | Notice of Effectiveness |
| Jun 17, 2026 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Jun 17, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 17, 2026 | CERT | Certification by an exchange approving securities for listing |
| Jun 15, 2026 | 8-A12B | Registration of securities |